BioCryst Pharmaceuticals' revenue forecast for ORLADEYO is very close to the analyst estimates, which suggests that the company's performance is in line with market expectations. This typically does not lead to significant stock price movements as there are no surprises to the market. However, the confirmation of expected performance can be seen as a positive sign of stability and may support the stock price.